This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the United States.
CLL is a type of cancer that comes from cells in the bone marrow called lymphocytes (a type of white blood cell). This can stop the normal functioning of other cells in the bone marrow. CLL gradually worsens over years. Zanubrutinib is a tyrosine kinase inhibitor (a protein that has many roles in the body). This can help slow down the spread of CLL. Rituximab is an immune therapy. It activates components of the immune system to attack cancer cells.
This trial is evaluating the safety and effectiveness of combining zanubrutinib and rituximab for the treatment of CLL. The main outcome that will be measured is the number of patients that achieve remission of the disease.
Who are they looking for?
This trial is looking to recruit 36 patients with CLL that has not been previously treated. Patients of child-bearing potential must be willing to use highly effective birth control. Patients must also have adequate kidney and liver function.
Patients will be excluded from the trial if they have previously been treated for CLL, if they have active infections or any serious medical condition, including other cancers. Female patients must not be pregnant or breast-feeding.
How will it work
There is one group in this trial. All patients will receive zanubrutinib and rituximab. The follow-up for this trial is 6-months following stopping zanubrutinib treatment. The number of participants who achieve remission during this period will be assessed.